Bourdon J-C
Inserm European Associated Laboratory, Department of Surgery and Molecular Oncology, University of Dundee, Inserm U858, CR-UK Cell Transformation Research Group, Dundee, UK.
Br J Cancer. 2007 Aug 6;97(3):277-82. doi: 10.1038/sj.bjc.6603886. Epub 2007 Jul 17.
p53, p63 and p73 are members of the p53 gene family involved in development, differentiation and response to cellular stress. p53 gene is a transcription factor essential for the prevention of cancer formation. The p53 pathway is ubiquitously lost in human cancer either by p53 gene mutation (60% of cancers) or by lost of cell signalling upstream and downstream of p53 in the remaining cancers expressing WTp53 gene. As p53 pathway inactivation is a common denominator to all cancers, the understanding of p53 tumour suppressor activity is likely to bring us closer to cancer therapy. However, despite all the experimental evidences showing the importance of p53 in preventing carcinogenesis, it is difficult in clinical studies to link p53 status to cancer treatment and clinical outcome. The recent discovery that p53 gene encodes for nine different p53 proteins (isoforms) may have a profound impact on our understanding of p53 tumour suppressor activity. Studies in several tumour types have shown that the nine different p53 isoforms are abnormally expressed in tumour tissues compared to normal cells. p53 protein isoforms modulate p53 transcriptional activity and cell fate outcome in response to stress. Regulation of p53 function in normal and tumour tissues in man is likely to be more complex than has been hitherto appreciated. Therefore, the tumour p53 status needs to be determined more accurately by integrating p53 isoform expression, functional p53 mutation analysis and a panel of antibodies specific of p53 and of its target genes.
p53、p63和p73是p53基因家族的成员,参与细胞发育、分化及对应激的反应。p53基因是预防癌症形成所必需的转录因子。在人类癌症中,p53通路普遍缺失,要么是由于p53基因突变(60%的癌症),要么是由于在表达野生型p53基因的其余癌症中p53上下游细胞信号传导缺失。由于p53通路失活是所有癌症的共同特征,了解p53肿瘤抑制活性可能会使我们更接近癌症治疗。然而,尽管所有实验证据都表明p53在预防癌变中的重要性,但在临床研究中很难将p53状态与癌症治疗及临床结果联系起来。最近发现p53基因编码九种不同的p53蛋白(异构体),这可能会对我们对p53肿瘤抑制活性的理解产生深远影响。对几种肿瘤类型的研究表明,与正常细胞相比,九种不同的p53异构体在肿瘤组织中异常表达。p53蛋白异构体可调节p53转录活性以及应激反应中的细胞命运结果。人类正常和肿瘤组织中p53功能的调节可能比迄今所认识到的更为复杂。因此,需要通过整合p53异构体表达、功能性p53突变分析以及一组针对p53及其靶基因的特异性抗体,更准确地确定肿瘤p53状态。